A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naive, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531).
- Topliss, Duncan (Primary Chief Investigator (PCI))
- Davids, Faeeza (Project Manager)
Project: Research